Jenna Logsdon, Ph.D. - Blogs Cannabis Supreme Court Patent Eligibility 101 Mayo Myriad Gene Segments IPR Antibodies AI Artificial Intelligence Life Cycle Management STAY UPDATED Follow Us Copyright © Oblon, McClelland, Maier ... Read More
PTAB Restates That Not All Combinations of Molecular Modifications are Obvious Cannabis Supreme Court Patent Eligibility 101 Mayo Myriad Gene Segments IPR Antibodies AI Artificial Intelligence Life Cycle Management STAY UPDATED Follow Us Copyright © Oblon, McClelland, Maier ... Read More
No Motivation to Modify Product-Specific Method with Method Features for Different Products Cannabis Supreme Court Patent Eligibility 101 Mayo Myriad Gene Segments IPR Antibodies AI Artificial Intelligence Life Cycle Management STAY UPDATED Follow Us Copyright © Oblon, McClelland, Maier ... Read More
Follow-On IPR Petitions - Institution Is Not Impossible But Difficult Cannabis Supreme Court Patent Eligibility 101 Mayo Myriad Gene Segments IPR Antibodies AI Artificial Intelligence Life Cycle Management STAY UPDATED Follow Us Copyright © Oblon, McClelland, Maier ... Read More
Claims Directed to Computerized Statistical Methods for Determining Haplotype Phase Are Patent Ineligible Cannabis Supreme Court Patent Eligibility 101 Mayo Myriad Gene Segments IPR Antibodies AI Artificial Intelligence Life Cycle Management STAY UPDATED Follow Us Copyright © Oblon, McClelland, Maier ... Read More
Another Example of Invalid Claims For Lack of Written Description and Enablement Cannabis Supreme Court Patent Eligibility 101 Mayo Myriad Gene Segments IPR Antibodies AI Artificial Intelligence Life Cycle Management STAY UPDATED Follow Us Copyright © Oblon, McClelland, Maier ... Read More
Trustees of Boston University v. Everlight Electronics Co. (Fed. Cir. July 25, 2018): Specification Must Enable the Full Scope of the Claimed Invention Cannabis Supreme Court Patent Eligibility 101 Mayo Myriad Gene Segments IPR Antibodies AI Artificial Intelligence Life Cycle Management STAY UPDATED Follow Us Copyright © Oblon, McClelland, Maier ... Read More
Pharma Claiming Practice Under Fire Cannabis Supreme Court Patent Eligibility 101 Mayo Myriad Gene Segments IPR Antibodies AI Artificial Intelligence Life Cycle Management STAY UPDATED Follow Us Copyright © Oblon, McClelland, Maier ... Read More
THE RECENT HHS' PLAN FOR GREATER FDA – USPTO COLLABORATION TO LOWER DRUG PRICES: WHY PHARMA PATENT COUNSEL NEEDS TO REVIEW FDA SUBMISSIONS Cannabis Supreme Court Patent Eligibility 101 Mayo Myriad Gene Segments IPR Antibodies AI Artificial Intelligence Life Cycle Management STAY UPDATED Follow Us Copyright © Oblon, McClelland, Maier ... Read More
In a Rule 12(b)(6) Motion to Dismiss Patentee's IPR Arguments Doom Its Complaint for Patent Infringement Cannabis Supreme Court Patent Eligibility 101 Mayo Myriad Gene Segments IPR Antibodies AI Artificial Intelligence Life Cycle Management STAY UPDATED Follow Us Copyright © Oblon, McClelland, Maier ... Read More